Haleon plc ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $14.8B+5.5% YoYTTM through 31 Dec 2025
Net Income $2.2B+24.2% YoYTTM through 31 Dec 2025
Free Cash Flow $3.1BTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| EBITDA Margin | 25.1% |
| Operating Margin | 21.9% |
| Net Margin | 15.1% |
Returns
10.1%ROE
5.1%ROA
Balance Sheet Health
Current Ratio0.92x
Cash & Equivalents$1.3B
Quality Metrics
Piotroski F-Score6 / 9
FCF Margin21.0%
Rule of 4024.4
Multi-Year Trend
RevenueFY2025: $11B
Diluted EPSFY2025: $0.19
Dividend
$0.13Per share, FY20261.42%Yield
Capital Allocation
Capex Intensity2.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| North America | $3.9B | -4.4% | View detailsExpected to return to growth in 2026 following leadership changes, streamlining of the business model, and clean retailer inventory levels. |
| EMEA and LatAm | $4.6B | -0.9% | View detailsContinued focus on driving category growth and productivity, despite a challenging macroeconomic backdrop in Brazil. |
| APAC | $2.6B | +0.5% | View detailsStrong growth opportunities in China and India, supported by GST nutraceutical reforms in India and full buyout of the China OTC joint venture. |
Financials converted at 0.7425 from GBP.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.